Download Snímek 1

7. 3. 2012
Benedikova A.
1. Cheng M., Chen Y. , Yu X. et al.:Diagnostic utility of
LunX mRNA in peripheral blood and pleural fluid in
patients with primary non-small cell lung cancer.
BMC Cancer (2008), 8:156.
1. Cheng M., Chen Y. , Yu X. et al.:Diagnostic utility of LunX
mRNA in peripheral blood and pleural fluid in patients with
primary non-small cell lung cancer. BMC Cancer (2008), 8:156.
Aim of the study:
To provide an evaluation of lung cancer tumour markers.
Methods:
qRT-PCR for LunX, CK19, CEA, VEGF-C and hnRNP A/B1 mRNA
levels in peripheral blood and pleural fluid from NSCLC
patients, patients with other epithelial cancer, benign lung
disease and from healthy volunteers
Conclusion:
LunX mRNA is the most specific gene marker for lung cancer and
has potential diagnostic utility when measured in the
peripheral blood and pleural fluid of NSCLC patients.
1. Cheng M., Chen Y. , Yu X. et al.:Diagnostic utility of LunX
mRNA in peripheral blood and pleural fluid in patients with
primary non-small cell lung cancer. BMC Cancer (2008), 8:156.
Methods:
Patients:
1. Cheng M., Chen Y. , Yu X. et al.:Diagnostic utility of LunX
mRNA in peripheral blood and pleural fluid in patients with
primary non-small cell lung cancer. BMC Cancer (2008), 8:156.
Methods:
qRT-PCR:
Specimens – 3 ml peripheral blood, 10 ml pleural fluid
RNA purification – using TRIZOL reagent
Reverse transcription – 4 µg RNA/40 µl reaction mixture
with oligo dT, M-MLV reverse transcriptase – cDNA
Real-time PCR - reaction mixture (50 µl) - specific primers,
TaqMan probe, 0,5 µg cDNA
quantification using standard curve
mRNA copies normalized to β-actin
1. Cheng M., Chen Y. , Yu X. et al.:Diagnostic utility of LunX
mRNA in peripheral blood and pleural fluid in patients with
primary non-small cell lung cancer. BMC Cancer (2008), 8:156.
Results:
LunX mRNA is the most specific gene marker for NSCLC cells in
peripheral blood as well as in pleural fluid
- LunX mRNA was detectable in the peripheral blood from only
NSCLC patients, not from patients with other epithelial cancer,
with pnemonia or healthy volunteers
- only the expression level of LunX mRNA was significantly
different between malignant and benign pleural fluid
- the other markers don´t show this specificity
1. Cheng M., Chen Y. , Yu X. et al.:Diagnostic utility of LunX
mRNA in peripheral blood and pleural fluid in patients with
primary non-small cell lung cancer. BMC Cancer (2008), 8:156.
Results:
Expression of LunX mRNA in peripheral blood is correlated with the
pathologic stage of NSCLC and decreases shortly following
treatment
- there is an association between different pathologic stages and
the LunX mRNA positive detection rate in peripheral blood, which
increase with increasing clinical severity
- the expression levels of LunX and CK19 mRNA in peripheral
blood decrease significantly in NSCLC patients after treatment
1. Cheng M., Chen Y. , Yu X. et al.:Diagnostic utility of LunX
mRNA in peripheral blood and pleural fluid in patients with
primary non-small cell lung cancer. BMC Cancer (2008), 8:156.
Conclusion:
In this study, the authors demonstrate that the detection of LunX
mRNA in peripheral blood and pleural fluid by quantitative real time
RT-PCR provides a specific and sensitive indication of the presence
of lung cancer cells.
LunX mRNA seems to be the most specific NSCLC gene marker
currently identified, and has clinical potential as an NSCLC
diagnostic tool.
Because LunX mRNA levels correlate with clinical severity and change
in response to treatment protocols, this marker may prove valuable
for NSCLC patients in the clinical decision-making process.
1. Cheng M., Chen Y. , Yu X. et al.:Diagnostic utility of LunX
mRNA in peripheral blood and pleural fluid in patients with
primary non-small cell lung cancer. BMC Cancer (2008), 8:156.
My conclusion:
The study is interesting because of the evaluation of 5 markers
together (LunX, CK19, CEA, VEGF-C and hnRNP A/B1).
The number of patients in some groups is too small.
There are only esophagus and breast cancer in the group of other
epithelial cancer.
They don´t write about using positive and negative qPCR controls.
Acknowledgements
Grants:
Investment in education development in molecular oncology
reg.n.:CZ.1.07/2.3.00/09.0089
This project is co-financed by European social fund in the Czech republic.
Thank You for Your Attention